Scribe Therapeutics Expands Collaboration With Sanofi To Advance In Vivo Genetic Medicines For Sickle Cell And Other Genomic Diseases; Scribe To Receive $40M Upfront, With The Potential For More Than $1.2B In Milestones Across All Programs
Portfolio Pulse from Happy Mohamed
Scribe Therapeutics has expanded its collaboration with Sanofi to advance in vivo genetic medicines for sickle cell and other genomic diseases. Scribe will receive $40M upfront, with the potential for more than $1.2B in milestones across all programs. The collaboration will leverage Scribe's CRISPR X-Editing (XE) technologies and Sanofi's capabilities in non-viral delivery to address sickle cell disease.
July 17, 2023 | 3:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sanofi's expanded collaboration with Scribe Therapeutics could potentially lead to breakthroughs in the treatment of sickle cell and other genomic diseases, which could boost Sanofi's revenues and reputation in the long run.
The expanded collaboration with Scribe Therapeutics gives Sanofi access to Scribe's CRISPR X-Editing technologies, which could potentially lead to breakthroughs in the treatment of sickle cell and other genomic diseases. This could boost Sanofi's revenues and reputation in the long run, hence the positive score.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100